Press Releases

Date Title and Summary Additional Formats
Toggle Summary Sirona Dx Introduces Imaging Mass Cytometry Services to Advance Biomarker Discovery and Therapeutic Development
Specialized CRO offers high-definition tissue imaging services for pharmaceutical and clinical research SOUTH SAN FRANCISCO, Calif. and PORTLAND, Ore. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sirona Dx, a leader in high-complexity genomics and proteomics services, today announced the introduction of
View HTML
Toggle Summary Laura Clague Named to Fluidigm Board of Directors
Senior Financial Leader with Broad Corporate and Biotech Expertise SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Laura M. Clague to the company’s Board of Directors and its audit committee.
View HTML
Toggle Summary Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technology, today
View HTML
Toggle Summary Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD
Combining high-performance automated microfluidics with easy-to-use software to streamline CNV detection for translational and clinical research SOUTH SAN FRANCISCO, Calif. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report third quarter financial results on Thursday, November 1, 2018 , after the close of the market.
View HTML
Toggle Summary Fluidigm Introduces Single-Cell Total RNA Sequencing Applications for C1
New single-cell protocols available for full-length, whole transcriptome sequencing using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today announced two new total RNA
View HTML
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis
Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD
Providing a best-in-class solution for immuno-oncology research, from RNA extraction to comprehensive data analysis, to advance therapeutic development SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded
View HTML
Toggle Summary Fluidigm to Participate at Upcoming Investor Events in September
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in three upcoming investor conferences in New York : Vikram Jog, Chief
View HTML
Toggle Summary Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting
Leading translational and clinical researchers to share new insights and best practices using Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd
View HTML